# Biotheus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biotheus

- Industry: Biotechnology
- Headquarters: Zhuhai, China
- Website: www.biotheus.com
- Total disclosed funding: $100M
- Latest round: Series B (Mar 2, 2021)
- Investors on record: 11

## About

Established in 2018, and based in Zhuhai, China, Biotheus Inc. specializes in biotechnology and biologic therapeutics. The company was founded by Andy Tsun, Joanne Sun, and Xiaolin Liu, who is also the CEO. Its headquarters is located in Zhuhai, China. Biotheus has raised USD 800.00 mn through a trade sale to BioNTech SE, marking its most recent funding round on November 13, 2024, which represents the total amount raised by the company. Over its operational years, Biotheus has completed five deals.

Biotheus specializes in the development and provision of innovative biotechnology solutions aimed at enhancing human health and wellness. The company's core offerings include a range of biologic therapeutics designed to address various medical conditions through advanced biological processes. These products are targeted primarily at healthcare providers, pharmaceutical companies, and research institutions, enabling them to improve patient outcomes through more effective treatment options. Biotheus has positioned its products in international markets including North America, Europe, and parts of Asia, aiming to meet the growing demand for advanced medical solutions.

The revenue model of Biotheus is primarily based on partnerships with healthcare organizations and direct sales of its proprietary therapeutic products. Transactions typically occur through long-term agreements with pharmaceutical companies that utilize Biotheus's biologics in their treatment protocols, facilitating a steady income flow. The company employs a B2B structure, where it collaborates directly with healthcare providers and research institutions to distribute its products. Specific pricing plans for their flagship therapeutics are established based on the value they provide in clinical outcomes, ensuring that clients receive high-quality solutions at competitive rates. This model effectively supports Biotheus's goal of expanding its market presence while delivering significant health benefits to a broad range of end-users.

In light of the acquisition by BioNTech, Biotheus Inc. plans to advance its immuno-oncology pipeline and expand its research and development, as well as its clinical trial capabilities, particularly in China. The recent funding, amounting to USD 800.00 mn, will be strategically utilized to support the development of new products and enhance the company's operational capacities. This includes launching new therapeutic solutions aimed at addressing unmet medical needs and entering into additional markets within North America and Europe by the end of 2025. The additional potential payment of approximately USD 150.00 mn contingent upon achieving certain milestones underscores the commitment to continued growth and innovation.

## Funding rounds

- Series B, Mar 2, 2021, $100M — General Atlantic, IDG Capital, CPE Funds Management, Cowin Capital, Golden China Fund, New Alliance Capital, HighLight Capital, Shanhai Capital, Shiyu Capital, Huajin Lingchuang Fund Management
- Series A, Jun 30, 2020 — New Alliance Capital, HighLight Capital, Shiyu Capital, Huajin Lingchuang Fund Management, Zhuhai Chengze Investment Management

## Investors

- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series A, Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A, Series B
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series A, Series B
- Huajin Lingchuang Fund Management (https://capitalatlas.ai/funds/huajin-lingchuang-fund-management) — Series A, Series B
- Zhuhai Chengze Investment Management — Series A
- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series B
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series B
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series B
- Golden China Fund (https://capitalatlas.ai/funds/golden-china-fund) — Series B
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series B